

Merck Update: HCV combo, Lambrolizumab and Corporate Restructuring Program

https://marketpublishers.com/r/MC30FC27FC1EN.html

Date: October 2013

Pages: 3

Price: US\$ 90.00 (Single User License)

ID: MC30FC27FC1EN

Abstracts

Merck announced restructuring (cost efficiency) program which is likely to benefit the company in the long run on the back delaying approval of Sugammadex, Odanacatib and Suvorexant from US regulatory authorities. Cost efficiency measures (\$2.5b cost saving by 2015) announced by the Company through workforce reduction across all functional divisions, head quarter relocation, out-licensing/discontinuation of some late stage programs. More focused attention on therapy areas where Merck has proven its abilities irrespective of unmet need and exploration of business commercial and innovation opportunities outside the company will redefine the Company for a better outlook. New R&D strategy will also have reduced focus on building Platform technologies.



I would like to order

Product name: Merck Update: HCV combo, Lambrolizumab and Corporate Restructuring Program

Product link: https://marketpublishers.com/r/MC30FC27FC1EN.html

Price: US\$ 90.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/MC30FC27FC1EN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:	
Last name:	
Email:	
Company:	
Address:	
City:	
Zip code:	
Country:	
Tel:	
Fax:	
Your message:	
	**All fields are required
	Custumer signature

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970